Pfizer's biologic, vaccine and gene therapy researchers should have a new headquarters in mid-2019, located in Chesterfield, Missouri.
It’s time again to call on you to nominate your Fierce 15 for 2017.
Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.
Xenon and partner Teva’s experimental pain drug TV-45070 has missed all endpoints in patients with pain following shingles.
New York City's bid to become a life sciences hotspot took another step forward this week with the help of a $5 million grant from the mayor's office.
How PAREXEL's New Ecosystem of Technology, Processes and Expertise is Transforming Drug Development
Patrick Soon-Shiong's outfit NantCell will acquire Altor Bioscience for two bucks a share.
The third BioGeneration Ventures Fund has hit $74 million as it attracts new investors.
Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders
Merck is mulling whether to file its CETP medication anacetrapib after posting some surprising positive topline data from the Reveal test.
RNA interference (RNAi) specialist Alnylam has hit the accelerator on its candidate drug for ultrarare porphyria diseases.
Neothetics said its phase 2 proof-of-concept study for its fat reduction therapy has flopped.